Drug Discovery & Development with Deep Learning Advanced Analytics
Solutions to Meet All Needs: From Small Biotech to Large Global Pharma
CertaraApril 6, 2023
Considerations for Pricing & Formulary Access for DRG-Funded Hospital Drugs
In the United States, treatments or medical services that require the patient be admitted into…
CertaraApril 6, 2023
Using Quantitative Systems Pharmacology Modelling to Accelerate Drug Development
Model informed drug development (in silico modelling) continues to be a game changer in accelerating…
CertaraMarch 29, 2023
Model-Informed Drug Development (MIDD) – EMA’s Advancement
Modelling and simulation (M&S) plays a crucial role in drug development. It allows information from…
CertaraMarch 29, 2023
Advancing Biopharmaceutics & Drug Formulation Using In Silico Modeling
Model-Informed Formulation Development (MIFD) Increases Speed and Certainty for New and Generic Drugs
CertaraMarch 22, 2023
Data-Backed Trial Design– Applying AI to Clinical Outcome Analysis
Global spending on clinical trials is expected to reach $68.9 billion per year by 2025…
CertaraMarch 17, 2023
Leveraging AI to Accelerate Drug Discovery: Vyasa Joins Certara
Applying Vyasa’s deep learning expertise to Certara products will enable our clients to expand how…
CertaraMarch 10, 2023
What you should know about FDA Project Optimus for your oncology drug approval
Historically, the dosing strategy for oncology drugs has focused on the maximum tolerated dose. This…
CertaraMarch 10, 2023
RAPS Sponsored Webcast: Oops, I messed Up! How to Avoid (and Fix) Common Regulatory Submission Mistakes
Oops, I made a mistake! Everyone has made or seen one, and sometimes it is…
CertaraMarch 9, 2023
